Patient Characteristics
| Parameters | LMPSMA alone | LMPSMA+SIRT | All patients |
| Patient count (n) | 31 | 5 | 36 |
| Age (y) | 71.9 (66.9–73.7) | 73.8 (64.8–78.7) | 72.4 (67.6–73.5) |
| Gleason score | 8 | 8 | 8 |
| Median PSA baseline (ng/mL) | 363.0 [4.9–6,970] | 49.5 [5.9–1,199] | 355.5 [4.9–6,970] |
| Median alkaline phosphatase (U/L) | 229.0 [47–1,028] | 81.0 [70–355] | 223.5 [47–1,028] |
| Median lactate dehydrogenase (U/L) | 448 [160–7,802] | 389 [192–442] | 435 [160–7,802] |
| PSMA radioligand therapy | |||
| Average number of cycles | 2 (2.0–3.6) | 3 (2.7–4.0) | 2.5 (2.2–3.6) |
| Cycles total | 89 | 17 | 106 |
| Average duration interval | 7.7 (6.5–8.5) | 7.5 (2.9–16.9) | 7.5 (6.7–9.3) |
| Average activity (GBq) | 6.2 (6.1–6.4) | 6.4 (5.7–7.5) | 6.2 (6.2–6.5) |
| ECOG PS (n) | |||
| 0–1 | 21 (67.8%) | 4 (80%) | 25 (69.4%) |
| 2 | 8 (25.8%) | 1 (20%) | 9 (25.0%) |
| 3 | 2 (6.4%) | 0 (0%) | 2 (5.0%) |
| Site of metastases (n) | |||
| Bone | 31 (100%) | 3 (60%) | 34 (94.4%) |
| Lymph node | 24 (77.4%) | 4 (80%) | 28 (77.7%) |
| Lung | 8 (25.8%) | 0 (0%) | 8 (22.2%) |
| Other | 1 (3.2%) | 0 (0%) | 1 (2.7%) |
| Previous therapy for mCRPC (n) | |||
| Docetaxel | 29 (93.5%) | 3 (60%) | 32 (88.8%) |
| Cabazitaxel | 14 (45.2%) | 2 (40%) | 16 (44.4%) |
| Abiraterone | 26 (83.8%) | 4 (80%) | 30 (83.3%) |
| Enzalutamide | 25 (80.6%) | 4 (80%) | 29 (80.5%) |
| Abiraterone and enzalutamide | 22 (70.1%) | 3 (60%) | 25 (69.4%) |
| 223Ra | 6 (19.3%) | 1 (20%) | 7 (19.4%) |
| EBRT, bone | 17 (54.8%) | 2 (40%) | 19 (52.8%) |
LMPSMA alone = liver metastasis–only PSMA therapy; LMPSMA+SIRT = liver metastasis PSMA therapy and SIRT; PSA = prostate-specific antigen; ECOG PS = Eastern Cooperative Oncology Group performance status; EBRT = external-beam radiation therapy.
Data in parentheses are 95% CIs or percentages; data in square brackets are ranges.